A detailed history of Eventide Asset Management, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 3,445,363 shares of MIRM stock, worth $143 Million. This represents 2.37% of its overall portfolio holdings.

Number of Shares
3,445,363
Previous 3,614,820 4.69%
Holding current value
$143 Million
Previous $124 Million 8.72%
% of portfolio
2.37%
Previous 2.18%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.68 - $44.74 $5.71 Million - $7.58 Million
-169,457 Reduced 4.69%
3,445,363 $134 Million
Q2 2024

Aug 13, 2024

BUY
$23.57 - $34.85 $7.41 Million - $11 Million
314,420 Added 9.53%
3,614,820 $124 Million
Q1 2024

May 15, 2024

BUY
$24.92 - $30.02 $15.9 Million - $19.1 Million
636,751 Added 23.91%
3,300,400 $82.9 Million
Q4 2023

Feb 20, 2024

SELL
$27.14 - $34.93 $25.8 Million - $33.2 Million
-950,000 Reduced 26.29%
2,663,649 $78.6 Million
Q4 2023

Feb 14, 2024

SELL
$27.14 - $34.93 $9.36 Million - $12 Million
-344,930 Reduced 8.71%
3,613,649 $107 Million
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $12.3 Million - $16.4 Million
499,378 Added 14.44%
3,958,579 $125 Million
Q2 2023

Aug 15, 2023

BUY
$23.51 - $30.09 $32.9 Million - $42.1 Million
1,400,000 Added 67.99%
3,459,201 $89.5 Million
Q1 2023

May 15, 2023

BUY
$19.19 - $24.1 $42,237 - $53,044
2,201 Added 0.11%
2,059,201 $49.5 Million
Q4 2022

Feb 13, 2023

BUY
$17.59 - $23.83 $13.8 Million - $18.6 Million
782,000 Added 61.33%
2,057,000 $40.1 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $25.5 Million - $37.5 Million
1,275,000 New
1,275,000 $26.8 Million

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.53B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.